A multicenter phase II study evaluated the safety and efficacy of the combination of the MEK1/2 inhibitors selumetinib and erlotinib in patients with previously treated advanced pancreatic cancer. The gene discussed is MAP2K1; the disease is familial pancreatic carcinoma.